The prognostic significance of metabolic response heterogeneity in metastatic colorectal cancer

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Hendlisz, Alain ^a   Deleporte, Amelie ^a   Delaunoit, Thierry ^b   Maréchal, Raphaël ^c   Peeters, Marc ^d   Holbrechts, Stéphane ^e   Van Den Eynde, Marc ^f   Houbiers, Ghislain ^g   Filleul, Bertrand ^b   Van Laethem, Jean Luc ^c   Ceyssens, Sarah ^d   Barbuto, Anna Maria ^e   Lhommel, Renaud ^f   Demolin, Gauthier ^g   Garcia, Camilo ^a   El Mansy, Hazem ^{a,b,c,d,e,f,g}   Ameye, Lieveke ^a   Moreau, Michel ^a   Guiot, Thomas ^a   Paesmans, Marianne ^a   Piccart, Martine ^a   Flamen, Patrick ^a   Santini, Daniele ^h   more..

^a JULES BORDET INSTITUTE   (Belgium)

^b Hospital de Jolimont   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e Centre Hospitalier Universitaire Ambroise Pare   (Belgium)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g Gastroenterology Department   (Belgium)

^h UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUORODEOXYGLUCOSE; SORAFENIB; 2-FLUORO-2-DEOXYGLUCOSE-6-PHOSPHATE; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; GLUCOSE 6 PHOSPHATE; NICOTINAMIDE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANEMIA THROMBOCYTOPENIA; ANOREXIA; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DRY SKIN; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC RESPONSE HETEROGENEITY; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RASH; SINGLE BLIND PROCEDURE; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOICE DISORDER; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; METASTASIS; MIDDLE AGED; MORTALITY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLUCOSE-6-PHOSPHATE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOGRAPHY; SURVIVAL RATE;

EID: 84947772627     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138341     Document Type: Article

References (38)

1. McDermott U, Downing JR, Stratton M.R. (2011) Genomics and the continuum of cancer care. N EnglJ Med 364: 340-350. doi: 10.1056/NEJMra0907178 PMID: 21268726
2. Greaves M, Maley C.C. (2012) Clonal evolution in cancer. Nature 481: 306-313. doi: 10.1038/ nature10762 PMID: 22258609
3. Aparicio S, Caldas C (2013) The implications of clonal genome evolution for cancer medicine. N EnglJ Med 368: 842-851. doi: 10.1056/NEJMra1204892 PMID: 23445095
4. Eisenhauer EA, Therasse P, Bogaerts J., Schwartz LH, Sargent D, Ford R, et al (2009) NSew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247. PMID: 19097774
5. Grothey A, Hedrick EE, Mass R.D., Sarkar S., Suzuki S, Ramanathan RK, et al (2008) Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 26:183-189. doi: 10.1200/JCO.2007.13.8099 PMID: 18182660
6. Grothey A, Van Cutsem E, Sobrero A, Siena S., Falcone A, Ychou M, et al (2012) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381: 303-312. doi: 10.1016/S0140-6736(12) 61900-X PMID: 23177514
7. Llovet JM, Ricci S, Mazzaferro V., Hilgard P, Gane E, Blanc J.F., et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390. doi: 10.1056/NEJMoa0708857 PMID: 18650514
8. Awada A, Gil T, Whenham N, Van Hamme J, Besse-Hammer T, Brendel E., et al. (2011) Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. J Clin Pharmacol 51:1674-1684. doi: 10.1177/0091270010386226 PMID: 21209247
9. Ott K, Weber WA, Lordick F, Becker K., Busch R, Herrmann K, et al (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24: 4692-4698. PMID: 16966684
10. Hoekstra CJ, Stroobants SG, Smit E.F., Vansteenkiste J., van Tinteren H, Postmus PE, et al (2005) Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23: 8362-8370. PMID: 16293866
11. Rousseau C, Devillers A, Sagan C., Ferrer L, Bridji B, Campion L., et al. (2006) Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 24: 5366-5372. PMID: 17088570
12. de Geus-Oei LF, van Laarhoven HW, Visser EP, Hermsen R, van Hoorn BA, Kamm YJ, et al. (2008) Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 19: 348-352. PMID: 17962202
13. Hendlisz A, Golfinopoulos V, Garcia C., Covas A, Emonts P, Ameye L., et al. (2012) Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol 23:1687-1693. doi: 10.1093/annonc/mdr554 PMID: 22112970
14. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M., Hutchings M, Mueller S.P., et al. (2014) Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol.
15. Cheson BD, Pfistner B, Juweid M.E., Gascoyne RD, Specht L, Horning SJ, et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25: 579-586. PMID: 17242396
16. Cheson BD, Fisher RI, Barrington S.F., Cavalli F., Schwartz LH, Zucca E, et al (2014) Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J Clin Oncol.
17. Kobe C, Dietlein M, Franklin J., Markova J, Lohri A, Amthauer H., et al. (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112: 3989-3994. doi: 10.1182/blood-2008-06-155820 PMID: 18757777
18. Young H, Baum R, Cremerius U., Herholz K, Hoekstra O, Lammertsma A.A., et al. (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. EurJCancer 35:1773-1782. PMID: 10673991
19. Wahl RL, Jacene H, Kasamon Y., Lodge M.A. (2009) From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50 Suppl 1:122S-150S. doi: 10.2967/ jnumed.108.057307 PMID: 19403881
20. Baselga J, Segalla JG, Roche H, Del Giglio A, Pinczowski H, Ciruelos E.M., et al. (2012) Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 30:1484-1491. doi: 10.1200/JCO.2011.36.7771 PMID: 22412143
21. Kupsch P, Henning BF, Passarge K, Richly H., Wiesemann K, Hilger RA, et al (2005) Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer 5:188-196. PMID: 16197622
22. Novello S, Vavala T, Levra MG, Solitro F, Pelosi E., Veltri A, et al. (2013) Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Clin Lung Cancer 14: 230-237. doi: 10.1016/j.cllc. 2012.10.004 PMID: 23276821
23. Ueno D, Yao M, Tateishi U., Minamimoto R, Makiyama K, Hayashi N., et al. (2012) Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer 12:162. doi: 10.1186/1471-2407-12-162 PMID: 22551397
24. Hendlisz A, Golfinopoulos V, Deleporte A., Paesmans M, Mansy H, Garcia C., et al. (2013) Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer 13:190. doi: 10.1186/1471-2407-13-190 PMID: 23587148
25. Giobbie-Hurder A., Gelber RD, Regan M.M. (2013) Challenges of guarantee-time bias. J Clin Oncol 31: 2963-2969. doi: 10.1200/JCO.2013.49.5283 PMID: 23835712
26. Marubini E, Valsecchi M.G. (1995) Analysing Survival data from clinical trials and observational studies: John Wiley & Sons, Chichester, England. 414 p.
27. Boellaard R, Oyen WJ, Hoekstra C.J., Hoekstra OS, Visser EP, Willemsen AT, et al (2008) The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 35: 2320-2333. doi: 10.1007/s00259-008-0874-2 PMID: 18704407
28. Gebhart G, Gamez C, Holmes E, Robles J., Garcia C, Cortes M, et al (2013) 18F-FDG PET/CTfor early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med 54:1862-1868. doi: 10.2967/jnumed.112. 119271 PMID: 24092940
29. Miller AB, Hoogstraten B, Staquet M, Winkler A. (1981) Reporting results of cancer treatment. Cancer 47: 207-214. PMID: 7459811
30. Therasse P, Arbuck SG, Eisenhauer E.A., Wanders J., Kaplan RS, Rubinstein L, et al. (2000) New Guidelines to Evaluate the Response to Treatment in Solid Tumors. Journal of the National Cancer Institute 92: 205-216. PMID: 10655437
31. Buvat I, Necib H, Garcia C, Wagner A., Vanderlinden B, Emonts P, et al (2012) Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer. Eur J Nucl Med Mol Imaging 39:1628-1634. PMID: 22710958
32. Bystrom P, Berglund A, Garske U., Jacobsson H, Sundin A, Nygren P., et al. (2009) Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol 20:1057-1061. doi: 10.1093/ annonc/mdn744 PMID: 19164458
33. de Geus-Oei LF, Vriens D, van Laarhoven HW, van der Graaf WT, Oyen WJ (2009) Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 50 Suppl 1: 43S-54S. doi: 10.2967/jnumed.108.057224 PMID: 19403879
34. Lastoria S, Piccirillo MC, Caraco C, Nasti G., Aloj L, Arrichiello C, et al (2013) Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab. J Nucl Med 54: 2062-2069. doi: 10.2967/jnumed.113.119909 PMID: 24136935
35. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg J.R., Tu D., Au HJ, et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048. PMID: 18003960
36. Bendell JC, Ervin TJ, Senzer NN, Richards D.A., Firdaus I., Lockhart AC, et al. (2012) Results of the XPECT study: A phase III randomized double blind, placebo controlled study of perifosine plus capecitabine (PCAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). J Clin Oncol 30.
37. Van Cutsem E., Peeters M, Siena S., Humblet Y, Hendlisz A, Neyns B., et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664. PMID: 17470858
38. Escudier B, Eisen T, Stadler W.M., Szczylik C., Oudard S, Staehler M, et al (2009) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27: 3312-3318. doi: 10.1200/JCO.2008.19.5511 PMID: 19451442